v3.26.1
Financial Instruments and Fair Value Measurements (Tables)
6 Months Ended
Mar. 31, 2026
Fair Value Disclosures [Abstract]  
Schedule of Cash and Equivalents
The following reconciles Cash and equivalents and Restricted cash reported within the Condensed Consolidated Balance Sheets as of March 31, 2026 and September 30, 2025, to the total amounts shown in the Condensed Consolidated Statements of Cash Flows:
March 31, 2026September 30, 2025
Cash and equivalents
$184.9 $225.5 
Restricted cash
8.5 3.1 
Cash and equivalents and restricted cash
$193.4 $228.6 
Schedule of Restricted Cash
The following reconciles Cash and equivalents and Restricted cash reported within the Condensed Consolidated Balance Sheets as of March 31, 2026 and September 30, 2025, to the total amounts shown in the Condensed Consolidated Statements of Cash Flows:
March 31, 2026September 30, 2025
Cash and equivalents
$184.9 $225.5 
Restricted cash
8.5 3.1 
Cash and equivalents and restricted cash
$193.4 $228.6 
Schedule of Notional Amounts of Derivative Instruments
The notional amounts of the Company’s foreign currency-related derivative instruments were as follows as of March 31, 2026 and September 30, 2025:
Hedge DesignationMarch 31, 2026September 30, 2025
Foreign exchange contracts(a)
Undesignated$82.7 $9.7 
Foreign exchange contracts(b)
Undesignated167.9 — 
(a)Represents hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and third-party transactions. Gains and losses on these instruments are recognized immediately in Other income (expense), net. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Gains and losses recognized to date on these instruments were not material to the Company's Condensed Consolidated Financial Statements.
(b)Represents hedges of the British pound sterling denominated purchase price of the pending acquisition of Owen Mumford entered during the second quarter of fiscal year 2026. Gains and losses on these instruments are recognized immediately in Other income (expense), net. Gains and losses recognized to date on these instruments were not material to the Company's Condensed Consolidated Financial Statements.